A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK)

T. Powles*, J. Brown, J. Larkin, R. Jones, C. Ralph, R. Hawkins, S. Chowdhury, E. Boleti, A. Bhal, K. Fife, A. Webb, S. Crabb, T. Geldart, R. Hill, J. Dunlop, P. E. Hall, D. McLaren, C. Ackerman, L. Beltran, P. Nathan

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK)'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science

Biochemistry, Genetics and Molecular Biology